Hypercalciuria in hyperprolactinemic rats: effects of benzthiazide.
There is evidence that prolactin (PRL) excess plays a role in the etiology of osteoporosis associated with human prolactinoma. Calcium balance in human hyperprolactinemia has not been thoroughly investigated. In the present study, rats with excess circulating PRL levels (male anterior pituitary-grafted Fischer 344 rats) had urinary calcium excretion twice that of control rats (4.16 +/- 0.43 v 2.25 +/- 0.30 mg/24h X 100 g BW). Calcium excretion expressed per mg of calcium intake was also high in pituitary-grafted rats. The excess calcium excretion in hyperprolactinemic rats was not accompanied by a concomitant rise in sodium excretion. This dissociation suggests that PRL has an effect on the renal handling of calcium. Since thiazide diuretics have a well-described hypocalciuric action, their effect was tested in these rats. In normal rats, benzthiazide, a long-acting agent, significantly reduced urinary calcium excretion in a dose-dependent fashion. Hyperprolactinemic rats responded to benzthiazide in a manner similar to control rats. In pituitary-grafted rats, benzthiazide also decreased the calcium excretion to intake ratio and normalized the calcium to sodium excretion ratio. Since the hypercalciuria of experimental hyperprolactinemia can be corrected by thiazide diuretics, these agents may have therapeutic potential in human PRL excess.
D000818:Animals; D001581:Benzothiadiazines / Q000494:pharmacology*; D002118:Calcium / Q000652:urine*; D002136:Calcium, Dietary / Q000378:metabolism; D004232:Diuretics; D004305:Dose-Response Relationship, Drug; D006966:Hyperprolactinemia / Q000652:urine*; D008297:Male; D009318:Natriuresis; D010903:Pituitary Gland, Anterior / Q000637:transplantation; D051381:Rats; D011916:Rats, Inbred F344; D049993:Sodium Chloride Symporter Inhibitors / Q000494:pharmacology*
D001581:Benzothiadiazines; D002136:Calcium, Dietary; D004232:Diuretics; D049993:Sodium Chloride Symporter Inhibitors; C004463:benzothiazide; D002118:Calcium